Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Narrative) (Details)

v2.4.0.8
Notes Payable (Narrative) (Details) (USD $)
3 Months Ended 9 Months Ended 1 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
General Electric Capital Corporation [Member]
Jun. 30, 2013
General Electric Capital Corporation [Member]
installment
Jun. 25, 2013
General Electric Capital Corporation [Member]
Sep. 30, 2012
Hercules Technology II, L.P. Notes [Member]
Jun. 24, 2013
Hercules Technology II, L.P. Notes [Member]
Jun. 25, 2013
Hercules Technology II, L.P. Notes [Member]
Sep. 30, 2012
Hercules Technology II, L.P. Notes [Member]
Sep. 30, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Jun. 25, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Sep. 30, 2013
Series X Warrants and Series AA Warrants [Member]
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Jun. 30, 2013
Series X Warrants and Series AA Warrants [Member]
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Jun. 30, 2013
Series HH Warrants [Member]
Jun. 30, 2013
Series HH Warrants [Member]
General Electric Capital Corporation [Member]
Jun. 25, 2013
Series HH Warrants [Member]
General Electric Capital Corporation [Member]
Jun. 30, 2013
Preferred Stock [Member]
Sep. 30, 2013
Preferred Stock [Member]
Jun. 30, 2013
Common Stock [Member]
Sep. 30, 2013
Common Stock [Member]
Sep. 30, 2013
Maximum [Member]
Sep. 30, 2013
Maximum [Member]
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Debt Instrument [Line Items]                                                
Debt Instrument, Face Amount             $ 25,000,000                                  
Debt instrument, interest rate             9.83%         10.00%                        
Number of shares underlying warrant issued                               301,205   301,205            
Exercise price of warrant issued                                 2.49 2.49         3.83  
Number of installment payments on notes payable           30                                    
Percentage of original principal amount of loan to be paid as a fee             4.00%                                  
Debt Instrument, Covenant Description         17,600,000                                      
Notes Payable         25,000,000             3,200,000                        
Unamortized debt discount         1,800,000   1,900,000     187,000                            
Debt issuance cost         783,000   881,000                                  
Principal payments on notes payable     5,982,156 620,480       620,000 1,300,000 4,400,000 620,000 4,781,333                        
Debt instrument, end of term fee                   250,000                            
Debt instrument, early payment penalty                   66,000                            
Loss on extinguishment of debt 0 0 (1,372,266) 0           429,000                            
Unamortized debt issuance cost                   176,000                            
Line of Credit Facility, Maximum Borrowing Capacity                                               35,000,000
Interest rate in addition to Prime rate                       6.75%                        
Interest rate in addition to amended agreement                       0.125%                        
Percentage of VWAP for conversion calculation                       90.00%                        
Number of days preceding the date of conversion request                       10 days                        
Minimum revenue from sales and licensing for mandatory repayment due                       2,000,000                        
Long-term embedded liability, estimated fair value                         943,000                      
Derivative, Gain (Loss) on Derivative, Net                       (388,000)                        
Series B preferred stock issued, shares                                     2,364.9 2,364.9        
Number of common shares underlying Series B Preferred Stock                           7,733,223 7,733,223                  
Shares conversion, number of common stock equivalent to each preferred stock                                         3,270 3,270    
Long-term Debt, Fair Value                       4,600,000                        
Debt Instrument, Unused Borrowing Capacity, Amount                       31,800,000                        
Interest expense related to debt $ 258,000 $ 147,000 $ 502,000 $ 407,000